Compare HOWL & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOWL | CCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Managed Health Care |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 29.6M |
| IPO Year | 2021 | 2022 |
| Metric | HOWL | CCEL |
|---|---|---|
| Price | $0.81 | $3.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 301.7K | 9.6K |
| Earning Date | 05-05-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 3.84% |
| EPS Growth | ★ 18.40 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $390.96 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $0.53 | $2.72 |
| 52 Week High | $2.23 | $5.76 |
| Indicator | HOWL | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 49.99 |
| Support Level | $0.80 | $3.18 |
| Resistance Level | $0.90 | $3.57 |
| Average True Range (ATR) | 0.08 | 0.30 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 3.35 | 22.73 |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.